ATP2A2 and metabolic dysfunction-associated steatotic liver disease: Further pathological analysis of the liver showed that AT-II treatment significantly improved NAFLD in mice injected with the empty control virus, while hepatic Serca2 knockdown markedly impaired AT-II's protective effect in the liver (Figs. 9F–K).